Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05784246 · ClinicalTrials.gov registry record · Phase 3
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
A Phase 3 study of Ulcerative Colitis, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT05784246 is a Phase 3 study of Ulcerative Colitis that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 60 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT05784246, a Phase 3 study of Ulcerative Colitis, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).
Conditions Studied
Interventions
- DRUG Mirikizumab IV
- DRUG Mirikizumab SC
Study Locations (20)
Other
- UZA - Edegem
- UZ Leuven - Leuven
- The Hospital for Sick Children - Toronto
- Hôpital Necker - Enfants Malades - Paris
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz - Mainz
- LMU-Campus Innenstadt - München
- Helios Klinikum Wuppertal - Wuppertal
- Shaare Zedek - Jerusalem
- Hadassah University Hospital, Ein Kerem - Jerusalem
- Schneider Children's Medical Center - Petah Tikva
- King Fahad Medical City - Rishon LeZiyyon
- Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer - Florence
- Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza - Roma
- Juntendo University Hospital - Bunkyō City
California
- University of California, San Francisco - San Francisco
Georgia
- Children's Center for Digestive Health Care, LLC - Atlanta
Indiana
- Riley Childrens Hospital - Indianapolis
Missouri
- Washington University - St Louis
New York
- Icahn School of Medicine at Mount Sinai - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-11-22 |
| Est. Completion | 2026-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05784246
The ClinicalTrials.gov registry entry for NCT05784246 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (97% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Mirikizumab IV is the first listed.
NCT05784246 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT05784246 about?
NCT05784246 is a clinical study titled "A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis". The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).
What is the current status of trial NCT05784246?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2023-11-22. Estimated completion is 2026-08.
What conditions does trial NCT05784246 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT05784246?
The interventions under investigation include: Mirikizumab IV (DRUG), Mirikizumab SC (DRUG).
Who is sponsoring clinical trial NCT05784246?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05784246 being conducted?
This trial has 20 study locations across California, Georgia, Indiana, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
RECRUITING · Phase 3
-
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.